Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily pill ease a stiff heart condition?

NCT ID NCT07021976

Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This trial tests whether an experimental drug called HRS-1893 can improve symptoms and reduce heart-related events in people with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and blocks blood flow. About 228 adults aged 18 to 85 with moderate symptoms will receive either HRS-1893 or a placebo. Researchers will measure how many people respond to treatment and track any side effects or major heart problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HRS-1893 tablets
What this could lead to
If successful, HRS-1893 could offer a new daily pill to ease symptoms and lower the risk of serious heart complications in people with obstructive hypertrophic cardiomyopathy.
What could go wrong
This is a phase III trial, but results are not yet known. The drug may not outperform placebo, and side effects are possible. Success in this trial does not guarantee regulatory approval or widespread availability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

228 people

The number who actually took part.

Started

Aug 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-85 years old, gender unlimited. 2. BMI\<35 kg/m2. 3. The diagnosis was obstructive hypertrophic cardiomyopathy. 4. Laboratory determination of echocardiography showed that Rest LVOT-G≥50 mmHg, or Rest LVOT-G≥30 mmHg and LVOT-G≥50 mmHg after Valsalva action. 5. Echocardiographic laboratory tests showed LVEF≥60%. 6. NYHA classification: Grade II - III. 7. Understand the study procedure and sign the informed consent in person, willing to strictly follow the clinical study protocol to complete the study. Exclusion Criteria: 1. Known or suspected invasive, genetic or storage diseases (e.g. Noonan syndrome, Fabre's disease, amyloidosis) that cause cardiac hypertrophy (similar to oHCM). 2. Had a history of severe valvular heart disease. 3. Abnormal laboratory test results during screening, or any other clinically significant abnormal screening laboratory values, which are determined by the researcher to be unsuitable for inclusion. 4. Other circumstances where the researchers consider the subjects unsuitable to participate in this trial, such as physical or mental illnesses or conditions that may increase the risk of the trial, affect the subjects' compliance with the protocol, or affect the subjects' completion of the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obstructive hypertrophic cardiomyopathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obstructive hypertrophic cardiomyopathy

Contacts and locations

Locations

  • Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

    Beijing, Beijing Municipality, 100032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.